{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T07:49:27Z","timestamp":1790495367556,"version":"4.1.0"},"reference-count":26,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2020,3,2]],"date-time":"2020-03-02T00:00:00Z","timestamp":1583107200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0228601","type":"journal-article","created":{"date-parts":[[2020,3,2]],"date-time":"2020-03-02T13:28:11Z","timestamp":1583155691000},"page":"e0228601","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":21,"title":["Zimbabwe\u2019s national third-line antiretroviral therapy program: Cohort description and treatment outcomes"],"prefix":"10.1371","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3756-3523","authenticated-orcid":true,"given":"Cleophas","family":"Chimbetete","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8931-4484","authenticated-orcid":true,"given":"Tinei","family":"Shamu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia","family":"Keiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2020,3,2]]},"reference":[{"key":"pone.0228601.ref001","doi-asserted-by":"crossref","first-page":"e132","DOI":"10.1016\/S2352-3018(16)00016-3","article-title":"The need for second-line antiretroviral therapy in adults in sub-Saharan Africa up to 2030: a mathematical modelling study","volume":"3","author":"J Estill","year":"2016","journal-title":"Lancet HIV"},{"key":"pone.0228601.ref002","doi-asserted-by":"crossref","first-page":"e82724","DOI":"10.1371\/journal.pone.0082724","article-title":"Persistent Difficulties in Switching to Second-Line ART in Sub-Saharan Africa\u2014A Systematic Review and Meta-Analysis","volume":"8","author":"Y Madec","year":"2013","journal-title":"PLoS One"},{"key":"pone.0228601.ref003","author":"WHO","year":"2016"},{"key":"pone.0228601.ref004","first-page":"1","article-title":"National Medicine and Therapeutics Policy Advisory Committee; The AIDS and TB Directorate Ministry of Health and Child Care","year":"2013","journal-title":"Guidelines for Antiretroviral Therapy for the Prevention and Treatment of HIV in Zimbabwe"},{"key":"pone.0228601.ref005","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.15585\/mmwr.mm6547a2","article-title":"Progress with scale-up of HIV viral load monitoring\u2014seven Sub-Saharan African countries, January 2015\u2013June 2016","author":"S Lecher","year":"2016","journal-title":"Morbidity and Mortality Weekly Report"},{"key":"pone.0228601.ref006","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1093\/jac\/dks310","article-title":"Characterization of HIV-1 antiretroviral drug resistance after second-line treatment failure in Mali, a limited-resources setting","volume":"67","author":"AI Maiga","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"pone.0228601.ref007","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1371\/journal.pone.0032144","article-title":"Virologic failure of protease inhibitor-based second-line antiretroviral therapy without resistance in a large HIV treatment program in South Africa","volume":"7","author":"JH Levison","year":"2012","journal-title":"PLoS One"},{"key":"pone.0228601.ref008","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ofid\/ofy005","article-title":"HIV-1 Drug Resistance and Third-Line Therapy Outcomes in Patients Failing Second-Line Therapy in Zimbabwe","volume":"5","author":"C Chimbetete","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"pone.0228601.ref009","doi-asserted-by":"crossref","first-page":"e588","DOI":"10.1016\/S2352-3018(18)30173-5","article-title":"HIV drug resistance in low-income and middle-income countries","volume":"5","author":"RL Hamers","year":"2018","journal-title":"Lancet HIV"},{"key":"pone.0228601.ref010","first-page":"769627","article-title":"Protease Inhibitor Resistance Is Uncommon in HIV-1 Subtype C Infected Patients on Failing Second-Line Lopinavir\/r-Containing Antiretroviral Therapy in South Africa","volume":"2011","author":"CL Wallis","year":"2011","journal-title":"AIDS Res Treat"},{"key":"pone.0228601.ref011","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s12981-015-0081-8","article-title":"Third-line antiretroviral therapy in Africa: effectiveness in a Southern African retrospective cohort study","volume":"12","author":"G Meintjes","year":"2015","journal-title":"AIDS Res Ther"},{"key":"pone.0228601.ref012","article-title":"Third-line antiretroviral therapy programme in the South African public sector","volume":"1","author":"M Moorhouse","year":"2018","journal-title":"JAIDS J Acquir Immune Defic Syndr"},{"key":"pone.0228601.ref013","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1097\/INF.0000000000001638","article-title":"Treatment Outcomes of Third-line Antiretroviral Regimens in HIV-infected Thai Adolescents","volume":"36","author":"W Prasitsuebsai","year":"2017","journal-title":"Pediatr Infect Dis J"},{"key":"pone.0228601.ref014","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0186726","article-title":"Outcomes of an HIV cohort after a decade of comprehensive care at Newlands Clinic in Harare, Zimbabwe: TENART cohort","volume":"12","author":"T Shamu","year":"2017","journal-title":"PLoS One"},{"key":"pone.0228601.ref015","first-page":"1","article-title":"A case report of untreatable HIV infection in Harare","author":"C Report","year":"2014","journal-title":"Zimbabwe"},{"key":"pone.0228601.ref016","doi-asserted-by":"crossref","DOI":"10.3402\/gha.v7.24861","article-title":"Second-line failure and first experience with third-line antiretroviral therapy in Mumbai, India","volume":"7","author":"S Khan","year":"2014","journal-title":"Glob Health Action"},{"key":"pone.0228601.ref017","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1097\/QAD.0b013e328351f5b2","article-title":"Treatment outcomes of patients on second-line antiretroviral therapy in resource-limited settings","volume":"26","author":"O Ajose","year":"2012","journal-title":"AIDS"},{"key":"pone.0228601.ref018","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1097\/QAD.0b013e32835221eb","article-title":"Genotype assays and third-line ART in resource-limited settings","volume":"26","author":"SB Lorenzana","year":"2012","journal-title":"AIDS"},{"key":"pone.0228601.ref019","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1097\/QAD.0b013e32835221eb","article-title":"Genotype assays and third-line ART in resource-limited settings: a simulation and cost-effectiveness analysis of a planned clinical trial","volume":"26","author":"SB Lorenzana","year":"2012","journal-title":"AIDS"},{"key":"pone.0228601.ref020","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0109148","article-title":"Cost-effectiveness of HIV drug resistance testing to inform switching to second line antiretroviral therapy in low income settings","volume":"9","author":"A Phillips","year":"2014","journal-title":"PLoS One"},{"key":"pone.0228601.ref021","doi-asserted-by":"crossref","DOI":"10.1093\/infdis\/jiw219","article-title":"Protease Inhibitor Resistance in the First 3 Years of Second-Line Antiretroviral Therapy for HIV-1 in Sub-Saharan Africa","volume":"214","author":"TS Boender","year":"2016","journal-title":"J Infect Dis"},{"key":"pone.0228601.ref022","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1093\/jac\/dks310","article-title":"Characterization of HIV-1 antiretroviral drug resistance after second-line treatment failure in Mali, a limited-resources setting","volume":"67","author":"AI Maiga","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"pone.0228601.ref023","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12981-018-0196-9","article-title":"Predictors of switch to and early outcomes on third-line antiretroviral therapy at a large public-sector clinic in Johannesburg, South Africa","volume":"15","author":"D Evans","year":"2018","journal-title":"AIDS Res Ther"},{"key":"pone.0228601.ref024","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.bjid.2012.08.022","article-title":"The Brazilian Journal of INFECTIOUS DISEASES High rate of virologic suppression with darunavir\/ritonavir plus optimized background therapy among highly antiretroviral-experienced HIV-infected patients: results of a prospective cohort study in S\u00e3o Paulo, Brazil","volume":"17","author":"JE Vidal","year":"2013","journal-title":"Brazilian J Infect Dis"},{"key":"pone.0228601.ref025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bjid.2013.04.001","article-title":"Virologic and immunologic effectiveness of darunavir-based salvage therapy in HIV-1-infected adults in a Brazilian clinical practice setting: results of a multicenter and retrospective cohort study","volume":"18","author":"KM Ribeiro","year":"2014","journal-title":"Brazilian J Infect Dis"},{"key":"pone.0228601.ref026","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s12981-015-0072-9","article-title":"Effectiveness and risk factors for virological outcome of darunavir-based therapy for treatment-experienced HIV-infected patients","volume":"12","author":"JA Mata-Mar\u00edn","year":"2015","journal-title":"AIDS Res Ther"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0228601","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,2]],"date-time":"2020-03-02T13:28:29Z","timestamp":1583155709000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0228601"}},"subtitle":[],"editor":[{"given":"Richard John","family":"Lessells","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2020,3,2]]},"references-count":26,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2020,3,2]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0228601","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,2]]}}}